Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-737-8 | CAS number: 110-12-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Specific investigations: other studies
Administrative data
- Endpoint:
- specific investigations: other studies
- Remarks:
- Lactational transfer
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Justification for type of information:
- The study was conducted as part of an OECD 443 extended 1-generation study to demonstrate that the test article or its metabolites can be transfered to the offspring via milk.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 019
Materials and methods
Test guideline
- Qualifier:
- no guideline required
- Principles of method if other than guideline:
- The principle of the study is to conduct an analysis of lactating animals exposed to the test article to determine if the test article can be found.
- GLP compliance:
- yes
- Type of method:
- in vivo
- Endpoint addressed:
- other: Lactational transfer
Test material
- Reference substance name:
- 5-methyl-2-hexanone
- IUPAC Name:
- 5-methyl-2-hexanone
- Reference substance name:
- 5-methylhexan-2-one
- EC Number:
- 203-737-8
- EC Name:
- 5-methylhexan-2-one
- Cas Number:
- 110-12-3
- Molecular formula:
- C7H14O
- IUPAC Name:
- 5-methylhexan-2-one
- Reference substance name:
- MIAK; Isoamyl methyl ketone
- IUPAC Name:
- MIAK; Isoamyl methyl ketone
- Details on test material:
- no data
Constituent 1
Constituent 2
Constituent 3
- Specific details on test material used for the study:
- Identification: Methyl isoamyl ketone (also referred to as MiAK; CAS No. 110 12-3)
Batch/Lot No.: TD16040801
Receipt Date: 05 Sep 2017
Physical Description: Clear, colorless liquid
Purity: 99.33%
Water Content: 0.0084%
Storage Conditions: Kept in a controlled temperature area set to maintain 18°C to 24°C
Supplier: Eastman Chemical Company
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Housing
On arrival, the F0 animals were group housed (up to 3 animals of the same sex) until cohabitation. During cohabitation, the animals were paired for mating in the home cage of the male. Following the breeding period, animals were individually housed. Animals were housed in solid-bottom cages containing appropriate bedding (Bed O’ Cobs®) equipped with an automatic watering valve.
Animals were separated during designated procedures/activities. Each cage was clearly labeled with a color-coded cage card indicating study, group, animal number(s), and sex. Cages were arranged on the racks in group order.
Animals were maintained in accordance with the Guide for the Care and Use of Laboratory Animals. The animal facilities at Charles River Ashland are accredited by AAALAC International.
Environmental Conditions
Target temperatures of 68°F to 78°F (20°C to 26°C) with a relative target humidity of 30% to 70% were maintained. A 12-hour light/12-hour dark cycle was maintained, except when interrupted for designated procedures. Ten or greater air changes per hour with 100% fresh air (no air recirculation) were maintained in the animal rooms.
Food
PMI Nutrition International, LLC Certified Rodent LabDiet® 5K96 Advanced Protocol® Verified Casein Diet 10 IF was provided ad libitum throughout the study, except during designated procedures. The feed used on this study needed to have a genistein-equivalent (aglycone) content of less than 300 ppm. PMI Nutrition International, LLC Certified Rodent LabDiet® 5K96 Advanced Protocol® Verified Casein Diet 10 IF consistently analyzed at less than 10.0 ppm total isoflavones (aglycone equivalents of genistein, daidzein, and glycitein).
The feed was analyzed by the supplier for nutritional components and environmental contaminants. Results of the analysis are provided by the supplier and are on file at the Testing Facility.
It is considered that there are no known contaminants in the feed that would interfere with the objectives of the study.
Water
Municipal tap water after treatment by reverse osmosis was freely available to each animal via an automatic watering system, except during designated procedures.
Periodic analysis of the water is performed, and results of these analyses are on file at the Testing Facility.
It is considered that there are no known contaminants in the water that could interfere with the outcome of the study.
Animal Enrichment
Animals were socially housed for psychological/environmental enrichment and were provided with environmental enrichment as appropriate to aid in maintaining the animals’ oral health, except during designated procedures.
Veterinary Care
Veterinary care was available throughout the course of the study; however, no examinations or treatments were required.
Administration / exposure
- Route of administration:
- inhalation: vapour
- Vehicle:
- air
- Details on exposure:
- Filtered air or MiAK vapor was administered as 6-hour, daily whole-body inhalation exposures, 7 days per week, at approximately the same time each day, according to the schedule below.
F0 females were exposed to either filtered air or vaporized MiAK concurrently with, and in the same exposure chambers, as animals on a concurrent extended one-generation reproductive toxicity study in Sprague Dawley rats.1 For all females, exposures were conducted for a minimum of 14 days prior to mating and continuing throughout the mating period. Following completion of the mating period, females (with no evidence of mating) continued to be exposed daily until 1 day prior to scheduled euthanasia. Males were not exposed to the test substance, and were only used for breeding purposes.
For females with evidence of mating, exposures during gestation were conducted up to and including Gestation Day 20, at which time exposure was suspended, through Lactation Day 4, to avoid confounding effects on parturition and nursing behavior. Exposures resumed on Lactation Day 5, and continued until Lactation Day 13, inclusively. During lactation, dams were separated from their litters during the exposure period. - Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 14 days pre-mating, maximum 2 weeks for mating, followed by gestation and to sacrifice at lactation day 13
- Frequency of treatment:
- daily
- Post exposure period:
- none
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 ppm
- Dose / conc.:
- 1 500 ppm
- Dose / conc.:
- 750 ppm
- Dose / conc.:
- 380 ppm
- No. of animals per sex per dose:
- 12
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- The study design involved exposing female rats to the test article beginning prior to gestation, throughout pregnancy and into lactation, with an analysis of milk and pup plasma for the test article.
Examinations
- Examinations:
- Observations
Clinical observations were performed once daily throughout the study. During the exposure period, these observations were performed prior to exposure. On exposure days, observations were also recorded at the approximate mid-point of exposure (animals visible in exposure chamber only), at the end of exposure, and 1–2 hours postexposure (see Appendix 1 - Study Protocol and Deviations).
During social housing, some observations (e.g., fecal observations) may not have been attributable to an individual animal.
Body Weights
F0 females were weighed individually weekly. Once evidence of mating was observed, female body weights were recorded on Gestation Days 0, 4, 7, 11, 14, 17, and 20 and on Lactation Days 1, 4, 7, 10, and 13.
Food Consumption
Food consumption was quantitatively measured weekly throughout the study period. Once evidence of mating was observed, female food consumption was recorded on Gestation Days 0, 4, 7, 11, 14, 17, and 20 and on Lactation Days 1, 4, 7, 10, and 13. - Positive control:
- No
Results and discussion
- Details on results:
- Whole-body inhalation of MiAK to female Crl:CD(SD) rats for 6 hours daily for at least 14 days prior to mating and continuing throughout the mating, gestation, and lactation periods until Lactation Day 13 resulted in quantifiable levels of MiAK in maternal milk and plasma that increased in a slightly greater than dose-proportional manner from 380 ppm to 750 ppm and roughly increased 2x from 750 ppm to 1500 ppm. For all groups, mean MiAK concentrations in milk were approximately 16-fold higher than in plasma. Even though plasma MiAK concentrations in pups were BLQ (<1000 ng/mL) at all exposure concentrations, the maternal plasma and milk concentration data demonstrate that the offspring were exposed to MiAK during both the gestation (in utero) and neonatal periods (through nursing).
Any other information on results incl. tables
Plasma MiAK Concentrations on Lactation/Postnatal Day 13 (ng/mL)
Target Exposure Concentration (ppm) | Lactation Day 13 | Postnatal Day 13 | |
Dams | Pups | ||
0 | Mean | All BLQ < (1000) | All BLQ < (1000) |
S.D. | |||
380 | Mean | 483 | All BLQ < (1000) |
S.D. | 881 | ||
750 | Mean | 1540 | All BLQ < (1000) |
S.D. | 2170 | ||
1500 | Mean | 3100 | All BLQ < (1000) |
S.D. | 5840 |
Milk MiAK Concentrations on Lactation Day 13 (ng/mL)
Target Exposure Concentration (ppm) | LD 13 | |
Females | ||
0 | Mean | All BLQ<(1000) |
S.D. | ||
380 | Mean | 7780 |
S.D. | 6610 | |
750 | Mean | 24,400 |
S.D. | 19,200 | |
1500 | Mean | 51,700 |
S.D. | 55,900 |
Applicant's summary and conclusion
- Conclusions:
- Whole-body inhalation of MiAK to female Crl:CD(SD) rats for 6 hours daily for at least 14 days prior to mating and continuing throughout the mating, gestation, and lactation periods until Lactation Day 13 resulted in quantifiable levels of MiAK in maternal milk and plasma that increased in a slightly greater than dose-proportional manner from 380 ppm to 750 ppm and roughly increased 2x from 750 ppm to 1500 ppm. For all groups, mean MiAK concentrations in milk were approximately 16-fold higher than in plasma. Even though plasma MiAK concentrations in pups were BLQ (<1000 ng/mL) at all exposure concentrations, the maternal plasma and milk concentration data demonstrate that the offspring were exposed to MiAK during both the gestation (in utero) and neonatal periods (through nursing).
- Executive summary:
The objective of this study was to detect the potential of the test substance, methyl isoamyl ketone (hereafter referred to as MiAK), to be secreted in maternal milk and to assess exposure of the pups via assessment of MiAK in maternal and pup plasma. F0females were exposed via whole-body inhalation for 6 hours daily for at least 14 days prior to mating and continuing throughout the mating, gestation, and lactation periods until Lactation Day 13, with the exception that exposure was suspended from Gestation Day 21 through Lactation Day 4. A concurrent control group was exposed to humidified, filtered air on a comparable regimen. Overall mean analyzed exposure concentrations were 380, 748, and 1500 ppm for Groups 2, 3, and 4, respectively.
The following parameters and end points were evaluated in this study: clinical signs, body weights, body weight gains, food consumption, reproductive performance, parturition, litter viability and survival, and exposure assessment in milk and plasma.
All F0females in the control, 380, 750, and 1500 ppm groups survived to the scheduled necropsy. Test substance-related increased incidences of red material around the nose in the 750 and 1500 ppm groups and red material around the mouth in the 1500 ppm group were noted at the end of exposure and 1–2 hours postexposure. In addition, increased incidences of hair loss on various body surfaces were noted for females in the 1500 ppm group at the daily examinations. No other test substance‑related clinical findings were noted at the daily examinations or at the midpoint of exposure, end of exposure, and 1–2 hours postexposure.
Test substance-related lower mean body weight gains, with corresponding effects on mean food consumption, were generally noted for females in the 1500 ppm group throughout the pre‑mating, gestation, and lactation periods, resulting in mean body weights that were lower (up to 5.9%) than the control group. In addition, a lower mean body weight gain was noted for females in the 750 ppm group during Study Days 7–13, without corresponding effects on mean food consumption or mean body weights. No other effects on mean body weights, body weight gains, and food consumption were noted at any exposure concentration.
No test substance-related effects were noted on reproductive performance (female mating, fertility, and conception), gestation length, or the process of parturition at any exposure concentration.
Survival, clinical condition, and growth of the F1generation was unaffected by test substance exposure at all exposure concentrations.
In conclusion, whole-body inhalation of MiAK to female Crl:CD(SD) rats for 6 hours daily for at least 14 days prior to mating and continuing throughout the mating, gestation, and lactation periods until Lactation Day 13 resulted in quantifiable levels of MiAK in maternal milk and plasma that increased in a slightly greater than dose-proportional manner from 380 ppm to 750 ppm and roughly increased 2x from 750 ppm to 1500 ppm. For all groups, mean MiAK concentrations in milk were approximately 16-fold higher than in plasma. Even though plasma MiAK concentrations in pups were BLQ (<1000 ng/mL) at all exposure concentrations, the maternal plasma and milk concentration data demonstrate that the offspring were exposed to MiAK during both the gestation (in utero) and neonatal periods (through nursing).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live2